China: Marketing Pfizer's Sutent for Gastrointestinal Tumors

Tuesday, October 25, 2011 - 6:30pm

Sunitinib malate (Sutent®) is a small-molecular inhibitor of tyrosine kinase receptors produced by Pfizer. It is used in the treatment of patients with gastrointestinal stromal tumours (GIST), a rare disease that affects the gastrointestinal tract. Patients suffering from GIST who develop resistance to or do not respond to the first-line treatment with Imatinib mesylate (Gleevec®) are treated with Sutent® as a second-line treatment. Furthermore, Sutent® has been proven effective for the treatment of advanced renal cell carcinoma (RCC) and pancreatic neuroendocrine tumours (pNET).This drug has netted revenues of approximately US$ 1.066 billion worldwide, for the year ended December 31st, 2010, with a year-on-year growth rate of approximately 11%. Much of that growth since 2008 has materialized, primarily, due to strong operational performance in international markets. China’s roaring economy and its soaring cancer rates has created a large captive demand for oncological treatments. By 2013, it is expected to have the third largest pharmaceutical market in the world, according to IMS Health’s Market Prognosis 2009. However, this large potential market is highly stratified and insurance coverage is irregular making affordability of Sutent® a huge bottleneck for the majority of cancer patients in China.

This presentation will propose a viable model for marketing Sutent® in China, while explaining the problem for reimbursement of this product in detail. It also serves to provide a general overview of the market’s landscape and regulatory aspects for approval of oncological drugs in China.

Team Innologix


Presented by Team Innologix
Tuesday, October 25, 2011
6:30-7:30pm, Instructional Centre, Room 335